INTERLEUKIN-2 AND THE TREATMENT OF LEUKEMIA AND LYMPHOMA

被引：4

作者：

BRENNER, MK

机构：

[1] Division of Bone Marrow Transplantation, Department of Hematology/Oncology, St. Jude Children's Research Hospital and Departments of Pediatrics and Medicine, University of Tennessee College of Medicine, Memphis, TN

来源：

LEUKEMIA & LYMPHOMA | 1991年 / 5卷 / 2-3期

基金：

美国国家卫生研究院;

关键词：

INTERLEUKIN-2; IL-2; TREATMENT; LEUKEMIA AND LYMPHOMA;

D O I：

10.3109/10428199109068109

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

As evidence has accumulated that allogeneic bone marrow transplantation provides therapeutic benefit by means of a graft versus malignancy effect, there has been a corresponding increase in interest in inducing or enhancing such an effect after chemotherapy and/or autologous bone marrow transplantation. Administration of Interleukin-2 may be one way of achieving this aim. Recent studies have shown the cytokine is tolerated after ABMT/chemotherapy in immunomodulatory doses and that the MHC unrestricted cytotoxic effector mechanisms induced can indeed discriminate between normal and malignant tissue. As always, larger scale randomized studies will be required before the therapeutic efficacy of this approach can been assessed. © 1991 Informa UK Ltd All rights reserved: reproduction in whole or part not permitted.

引用

页码：77 / 83

页数：7

共 36 条

[21]

Macdonald D., Jiang Y.Z., Swirsky D., Vulliamy T., Morilla R., Bungey J., Barrett A.J., Acute Myeloid leukemia relapsing following interleukin 2 treatment expresses the alpha chain of the interleukin 2 receptor, Brit. J. Hematol, 77, pp. 43-49, (1991)

[22]

Rosolen A., Nakanishi M., Poplack D.G., Expression of Interleukin-2 receptor β subunit in hematopoietic malignancies, Blood, 73, pp. 1968-1972, (1989)

[23]

Carron J.A., Cawley J.C., IL-2 and myelopoiesis: IL-2 induces blast cell proliferation in some cases of acute myeloid leukemia, Br. J. Haematol, 73, pp. 168-172, (1989)

[24]

Rosenberg S.A., Lotze M.T., Mule J.J., New approaches to the immunotherapy of cancer using Interleukin-2, Ann. Intern. Med, 108, pp. 853-864, (1988)

[25]

Smith K.A., Interleukin-2: Inception, impact and implications, Science, 240, pp. 1169-1176, (1988)

[26]

Malkovsky M., Brenner M.K., Hunt R., Rastan S., Dore C., Brown S., North M.E., Asherson G.L., Prentice H.G., Medawar P., T-cell depletion prevents potentiation of graft versus host disease by IL-2, Cell Immunol, 103, (1986)

[27]

Sykes M., Romick M.L., Hoyles K.A., Sachs D.H., In vivo administration of Interleukin 2 plus T cell-depleted syngeneic marrow prevents graft-versus-host disease mortality and permits alloengraftment, J. Exp. Med, 171, pp. 645-658, (1990)

[28]

Sykes M., Romick M.L., Sachs D.H., Interleukin 2 prevents graft-versus-host disease while preserving the graft-versus-leukemia effect of allogeneic T cells, Proc. Natl. Acad. Sci. USA, 87, pp. 5633-5637, (1990)

[29]

Gottlieb D.J., Brenner M.K., Heslop H.E., A phase I clinical trial of recombinant Interleukin 2 following high dose chemo-radiotherapy for haematological malignancy: Applicability to the elimination of minimal residual disease, Br. J. Cancer, 60, pp. 610-615, (1989)

[30]

Heslop H.E., Duncombe A.S., Reittie J.E., Bello-Fernandez C., Gottlieb D.J., Prentice H.G., Hoffbrand A.V., Brenner M.K., Interleukin 2 infusion induces hemopoietic growth factors and modifies marrow recovery after chemotherapy or autologous bone marrow transplantation, Br. J. Haematol, 77, pp. 237-244, (1991)

← 1 2 3 4 →